Korro Bio Management
Management criteria checks 1/4
Korro Bio's CEO is Ram Aiyar, appointed in Nov 2020, has a tenure of 4.08 years. total yearly compensation is $2.86M, comprised of 17.4% salary and 82.6% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth $190.05K. The average tenure of the management team and the board of directors is 2.1 years and 0.7 years respectively.
Key information
Ram Aiyar
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 17.4% |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.1yrs |
| Board average tenure | less than a year |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$88m |
| Jun 30 2024 | n/a | n/a | -US$85m |
| Mar 31 2024 | n/a | n/a | -US$81m |
| Dec 31 2023 | US$3m | US$498k | -US$81m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$69m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$1m | US$473k | -US$58m |
Compensation vs Market: Ram's total compensation ($USD2.86M) is above average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Ram's compensation has increased whilst the company is unprofitable.
CEO
Ram Aiyar (46 yo)
4.1yrs
Tenure
US$2,858,230
Compensation
Mr. Ram Aiyar, Ph.D. MBA, serves as Director of Triveni Bio Inc. Mr. Aiyar has been President of Korro Bio, Inc. since November 20201, Director since November 03, 2023 and also has been its Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman of the Board | 1.1yrs | US$534.53k | 0.37% $ 1.4m | |
| CEO, President & Director | 4.1yrs | US$2.86m | 0.049% $ 190.1k | |
| Co-Founder & Independent Director | no data | US$171.80k | no data | |
| Chief Financial Officer | 3.6yrs | US$1.32m | 0% $ 0 | |
| Co-Founder & Advisor | no data | no data | no data | |
| Co-Founder & Advisor | no data | no data | no data | |
| Chief Operating Officer | 1.3yrs | no data | no data | |
| Senior VP & General Counsel | no data | no data | no data | |
| Senior VP and Head of People & Culture | 2.1yrs | no data | no data | |
| VP & Head of CNS biology | no data | no data | no data | |
| Senior VP & Head of Platform | 2.1yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.1yrs
Average Tenure
49.5yo
Average Age
Experienced Management: KRRO's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman of the Board | 1.1yrs | US$534.53k | 0.37% $ 1.4m | |
| CEO, President & Director | 1.1yrs | US$2.86m | 0.049% $ 190.1k | |
| Co-Founder & Independent Director | 1.1yrs | US$171.80k | no data | |
| Independent Director | 1.1yrs | US$173.15k | no data | |
| Independent Director | 1.1yrs | US$172.03k | no data | |
| Independent Director | 1.1yrs | US$304.23k | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data |
0.7yrs
Average Tenure
56yo
Average Age
Experienced Board: KRRO's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:43 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Korro Bio, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Catherine Novack | JonesTrading Institutional Services, LLC |